IRIS UniCatt

Lombardi, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.675
EU - Europa 1.343
AS - Asia 782
SA - Sud America 203
AF - Africa 23
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.038
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.646
SE - Svezia 368
SG - Singapore 306
IT - Italia 258
CN - Cina 252
BR - Brasile 191
FR - Francia 137
DE - Germania 124
PL - Polonia 119
IE - Irlanda 100
IN - India 65
ID - Indonesia 64
FI - Finlandia 55
GB - Regno Unito 40
RU - Federazione Russa 38
BE - Belgio 23
HK - Hong Kong 18
CA - Canada 17
NL - Olanda 17
KR - Corea 15
ES - Italia 10
IR - Iran 10
UA - Ucraina 10
AT - Austria 9
CH - Svizzera 9
CI - Costa d'Avorio 9
JP - Giappone 6
MA - Marocco 6
MX - Messico 6
PK - Pakistan 6
TR - Turchia 6
CZ - Repubblica Ceca 5
TW - Taiwan 5
VN - Vietnam 5
AR - Argentina 4
AU - Australia 4
IQ - Iraq 4
LT - Lituania 4
NZ - Nuova Zelanda 4
EC - Ecuador 3
LV - Lettonia 3
MY - Malesia 3
PA - Panama 3
ZA - Sudafrica 3
BD - Bangladesh 2
BY - Bielorussia 2
CL - Cile 2
DK - Danimarca 2
EU - Europa 2
IL - Israele 2
KZ - Kazakistan 2
NG - Nigeria 2
OM - Oman 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.038
Salva come PNG Salva come JPEG
Città #
Chandler 486
Singapore 209
Ashburn 130
Warsaw 116
New York 113
Dublin 97
Milan 76
Jakarta 64
San Mateo 55
Rome 50
Helsinki 48
Beijing 42
Boston 42
Princeton 42
Marseille 41
Wilmington 35
The Dalles 28
Fairfield 27
Ann Arbor 26
Los Angeles 26
Moscow 26
Nanjing 24
Brussels 23
Woodbridge 21
Hefei 20
Seattle 18
Frankfurt am Main 17
Nuremberg 17
Düsseldorf 16
Houston 16
Jacksonville 16
Pune 16
Cambridge 15
Amsterdam 14
Hong Kong 14
Seoul 14
São Paulo 14
London 13
Augusta 12
Cattolica 12
Lauterbourg 12
Redwood City 12
Dearborn 10
Guangzhou 10
Abidjan 9
Santa Clara 9
Toronto 8
Andover 7
Hyderabad 7
Nanchang 7
Ottawa 7
Turin 7
Vienna 7
Brooklyn 6
Hangzhou 6
Norwalk 6
Belo Horizonte 5
Bologna 5
Chicago 5
Columbus 5
Jinan 5
Kish 5
Paris 5
Roubaix 5
Shenyang 5
Tokyo 5
Bremen 4
Brno 4
Carate Brianza 4
Dong Ket 4
Edinburgh 4
Falkenstein 4
Jiaxing 4
Lancaster 4
Madrid 4
Mountain View 4
North Bergen 4
Padova 4
Phoenix 4
Recife 4
Sacramento 4
San Diego 4
Tianjin 4
Zurich 4
Alcalá de Henares 3
Atlanta 3
Auckland 3
Baghdad 3
Cagliari 3
Campinas 3
Changsha 3
Chongqing 3
Council Bluffs 3
Curitiba 3
Fort Worth 3
Guarujá 3
Lahore 3
Leawood 3
Mumbai 3
Munich 3
Totale 2.391
Salva come PNG Salva come JPEG
Nome #
Evaluation of the effect of a floxed Neo cassette within the dystroglycan (Dag1) gene 282
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 112
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 112
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 107
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 100
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 99
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 98
Sarilumab use in severe SARS-CoV-2 pneumonia 96
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 95
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 85
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 83
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 83
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 81
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 81
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 81
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 80
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 78
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 78
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 77
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 76
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 75
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 73
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 73
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 73
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 73
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 73
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 72
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 71
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 68
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 68
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 66
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 66
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 61
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV 61
Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients? 59
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 57
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 57
Evaluation of doravirine-based regimen population target in a large Italian clinical center 57
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 55
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort study 54
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 52
Quantification of total hiv dna as a marker to measure viral reservoir: Methods and potential implications for clinical practice 51
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 47
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 45
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 45
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 44
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 41
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 40
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 39
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 39
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 39
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 38
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 36
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 35
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 34
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 32
Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype 27
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 27
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 26
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 25
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy 19
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 18
Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome 17
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops 13
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 8
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 8
Totale 4.141
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 0 0 0 0 0 0 0 0 0 0 0 6
2020/2021151 25 11 5 7 14 10 9 2 12 12 34 10
2021/2022483 12 3 10 52 11 7 38 78 14 44 60 154
2022/20231.220 168 187 97 181 75 143 66 94 137 8 52 12
2023/2024684 16 147 17 65 26 138 47 15 18 28 97 70
2024/20251.176 23 18 161 54 103 71 97 74 161 120 256 38
Totale 4.141